MarketMacrophage-1 antigen
Company Profile

Macrophage-1 antigen

Macrophage-1 antigen is a complement receptor ("CR3") consisting of CD11b and CD18.

Function
Macrophage-1 antigen (hereafter complement receptor 3 or CR3) (CD11b/CD18) is a human cell surface receptor found on B and T lymphocytes, polymorphonuclear leukocytes (mostly neutrophils), NK cells, and mononuclear phagocytes like macrophages. CR3 is a pattern recognition receptor, capable of recognizing and binding to many molecules found on the surfaces of invading bacteria. CR3 also recognizes iC3b when bound to the surface of foreign cells. iC3b is generated by proteolysis of C3b and binding to the receptor causes phagocytosis and destruction of the foreign cell opsonized with iC3b. CR3 belongs to a family of cell surface receptors known as integrins (because they share this particular β chain, they are referred to as β2-integrins), which are extremely widely distributed throughout nature and which generally are important in cellular adhesion, migration, phagocytosis and other cell-cell interactions in a variety of cells and circumstances. CR3 has also been shown to mediate phagocytosis of the Lyme disease causing bacterium, Borrelia burgdorferi, in the absence of iC3b opsonization. == CR3 and CR4 ==
CR3 and CR4
CR3 (integrin αMβ2) and CR4 (integrin αXβ2, composed of CD11c and CD18), both members of the β2-integrin family, are generally thought to exhibit overlapping functions in myeloid cells and certain lymphoid populations. It has been shown that both CR3 and CR4 are found in mice and humans. Together, CR3 and CR4 are involved in various functions of the T and B lymphocytes and NK cells. For instance, while both CR3 and CR4 are involved in adhesion, migration and proliferation of B cells, they are involved in enhancing complement-dependent cytotoxicity in NK cells. == CR3 and CR4 for Disease Therapy ==
CR3 and CR4 for Disease Therapy
Immunomodulatory therapies often aim for an induced reduction of symptoms in inflammatory disease or supported elimination of malignancies. In vitro and in vivo experiments suggest a response of CR3 and CR4 to enable complement-dependent cell cytotoxicity towards antibody-coated cancer cells. Such biological therapeutic targeting is characterized by lowering autoimmune inflammation or enhancing anti-cancer vaccination effects. Leukadherin-1, a CR3 agonist molecule, has been shown to suppress human innate inflammatory signals. Its anti-inflammatory effect mediation further provides support for its therapeutic promise in animal models of vascular injury. ==Synonyms and abbreviations==
Synonyms and abbreviations
• CR3 • CD11b/CD18 • Macrophage 1 antigen (Mac-1) ==See also==
tickerdossier.comtickerdossier.substack.com